Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism
CB Burness, CM Perry - Drugs, 2014 - Springer
Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, is approved for the initial treatment
of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of …
of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of …
[HTML][HTML] Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
S Harder - Thrombosis Journal, 2014 - Springer
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …
Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study)
E Romualdi, MP Donadini, W Ageno - Expert review of …, 2011 - Taylor & Francis
Over recent years, research on anticoagulant drugs has been guided by the requirement for
convenient administration and a wide therapeutic window to allow fixed dosing without the …
convenient administration and a wide therapeutic window to allow fixed dosing without the …
Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach
JI Arcelus, P Domenech… - Clinical and Applied …, 2015 - journals.sagepub.com
Anticoagulation therapy is the standard treatment of patients with symptomatic venous
thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until …
thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until …
The use of rivaroxaban for short-and long-term treatment of venous thromboembolism
AT Cohen, M Dobromirski - Thrombosis and haemostasis, 2012 - thieme-connect.com
Venous thromboembolism (VTE) is a major healthcare concern and affects more than 1.6
million individuals each year worldwide. Long-term complications include recurrent VTE …
million individuals each year worldwide. Long-term complications include recurrent VTE …
[HTML][HTML] Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies
HR Buller - Blood, 2012 - Elsevier
Abstract Abstract 20 Harry R. Büller, MD, PhD on behalf of the EINSTEIN Investigators.
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …
[HTML][HTML] XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein …
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary
embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related …
embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related …
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism
B van Bellen, L Bamber… - … medical research and …, 2014 - Taylor & Francis
Abstract Objective: The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
Einstein–PE Investigators - New England journal of medicine, 2012 - Mass Medical Soc
Background A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …
Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients
L Jara-Palomares, R Sanchez-Oro-Gomez… - Thrombosis research, 2014 - Elsevier
Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …
相关搜索
- pulmonary embolism vein thrombosis
- venous thromboembolism rivaroxaban in the treatment
- pulmonary embolism rivaroxaban for the treatment
- venous thromboembolism prevention of recurrences
- oral rivaroxaban einstein dvt
- standard therapy vein thrombosis
- pulmonary embolism reduction in the length
- reduction in the length vein thrombosis
- venous thromboembolism pharmacodynamic evaluation
- rationale and design vein thrombosis
- long term vein thrombosis
- venous thromboembolism use of rivaroxaban
- venous thromboembolism considerations for the treatment
- pulmonary embolism length of stay
- length of stay vein thrombosis